US EditionMazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
The Phase 3 GLORY-2 trial showed an 18.6% mean weight loss at 60 weeks in obese Chinese adults, with 44% achieving 20% or more weight reduction, Innovent reported.
- Earlier this month, Innovent Biologics announced GLORY-2 met primary and all secondary endpoints in 462 Chinese adults over 60 weeks.
- China faces a high obesity burden where developing mazdutide offers an evidence-based alternative to metabolic surgery for Chinese patients with moderate-to-severe obesity.
- At Week 60, the mazdutide 9 mg group showed mean weight reduction of 18.55% versus 3.02% for placebo, with 44.0% achieving ≥20% weight loss compared to 2.6% in the placebo group.
- Innovent Biologics plans to submit an NDA for mazdutide 9 mg to the Center for Drug Evaluation of China’s NMPA in the near term and aims to expand its therapeutic potential through lifecycle management.
- Beyond weight loss, MRI-PDFF liver fat subset showed −71.9% reduction with mazdutide 9 mg versus 5.1% placebo, safety data indicate favorable tolerability despite gastrointestinal adverse events and a 2.9% discontinuation rate, and cardiometabolic endpoints improved.
30 Articles
30 Articles
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, and ophthalmologic diseases, announces…
Coverage Details
Bias Distribution
- 76% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
